Michael Ulz
Stock Analyst at Morgan Stanley
(4.55)
# 339
Out of 4,479 analysts
94
Total ratings
54.55%
Success rate
33.71%
Average return
Main Sectors:
Top Industries:
30 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $49 | $18.06 | +171.32% | 9 | Jun 28, 2024 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $105 | $51.54 | +103.73% | 1 | Jun 27, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $164 → $250 | $247.61 | +0.97% | 7 | Jun 25, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $53 → $57 | $33.68 | +69.24% | 3 | Jun 18, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $36 → $27 | $25.22 | +7.06% | 4 | May 13, 2024 | |
| DYN Dyne Therapeutics | Initiates: Overweight | $40 | $34.65 | +15.44% | 1 | Apr 30, 2024 | |
| KYTX Kyverna Therapeutics | Initiates: Overweight | $40 | $8.05 | +396.89% | 1 | Mar 4, 2024 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $3 → $7 | $3.22 | +117.39% | 7 | Feb 27, 2024 | |
| GUTS Fractyl Health | Initiates: Overweight | $18 | $4.44 | +305.41% | 1 | Feb 27, 2024 | |
| CABA Cabaletta Bio | Maintains: Overweight | $28 → $25 | $7.39 | +238.29% | 4 | Nov 29, 2023 | |
| IONS Ionis Pharmaceuticals | Maintains: Equal-Weight | $45 → $48 | $45.14 | +6.34% | 4 | Nov 3, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $59 → $63 | $110.36 | -42.91% | 8 | Oct 27, 2023 | |
| AKRO Akero Therapeutics | Maintains: Overweight | $70 → $33 | $22.38 | +47.45% | 3 | Oct 11, 2023 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $15 → $27 | $7.52 | +259.04% | 2 | Aug 16, 2023 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $7 → $5 | $11.37 | -56.02% | 5 | Aug 14, 2023 | |
| THRD Third Harmonic Bio | Maintains: Equal-Weight | $5 → $7 | $12.24 | -42.81% | 3 | Aug 11, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Equal-Weight | $5 → $4 | $0.80 | +400.00% | 4 | Aug 7, 2023 | |
| ALVR AlloVir | Reiterates: Overweight | $20 | $0.74 | +2,621.09% | 2 | Aug 7, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $20 → $23 | $7.73 | +197.54% | 3 | May 23, 2023 | |
| SNTI Senti Biosciences | Maintains: Equal-Weight | $3 → $2 | $0.39 | +412.82% | 3 | Mar 24, 2023 | |
| RCKT Rocket Pharmaceuticals | Initiates: Overweight | $45 | $19.78 | +127.50% | 1 | Feb 1, 2023 | |
| XLO Xilio Therapeutics | Maintains: Overweight | $20 → $10 | $0.89 | +1,023.60% | 3 | Jan 27, 2023 | |
| ALLK Allakos | Maintains: Equal-Weight | $6 → $8 | $0.84 | +851.70% | 5 | Jan 27, 2023 | |
| TSHA Taysha Gene Therapies | Downgrades: Equal-Weight | $3 | $2.16 | +38.89% | 1 | Jan 27, 2023 | |
| VIR Vir Biotechnology | Upgrades: Equal-Weight | $18 → $30 | $8.85 | +238.98% | 1 | Jan 27, 2023 | |
| IGMS IGM Biosciences | Maintains: Equal-Weight | $25 → $30 | $6.40 | +368.75% | 3 | Mar 30, 2022 | |
| ITOS iTeos Therapeutics | Initiates: Outperform | n/a | $14.44 | - | 1 | Oct 8, 2020 | |
| MRSN Mersana Therapeutics | Initiates: Outperform | n/a | $1.86 | - | 1 | May 8, 2018 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | n/a | $40.96 | - | 1 | Nov 3, 2017 | |
| FOLD Amicus Therapeutics | Maintains: Outperform | n/a | $9.85 | - | 2 | Jul 12, 2017 |
Silence Therapeutics
Jun 28, 2024
Maintains: Overweight
Price Target: $45 → $49
Current: $18.06
Upside: +171.32%
Viking Therapeutics
Jun 27, 2024
Initiates: Overweight
Price Target: $105
Current: $51.54
Upside: +103.73%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Equal-Weight
Price Target: $164 → $250
Current: $247.61
Upside: +0.97%
Mirum Pharmaceuticals
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $33.68
Upside: +69.24%
Arrowhead Pharmaceuticals
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $25.22
Upside: +7.06%
Dyne Therapeutics
Apr 30, 2024
Initiates: Overweight
Price Target: $40
Current: $34.65
Upside: +15.44%
Kyverna Therapeutics
Mar 4, 2024
Initiates: Overweight
Price Target: $40
Current: $8.05
Upside: +396.89%
Fate Therapeutics
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $3.22
Upside: +117.39%
Fractyl Health
Feb 27, 2024
Initiates: Overweight
Price Target: $18
Current: $4.44
Upside: +305.41%
Cabaletta Bio
Nov 29, 2023
Maintains: Overweight
Price Target: $28 → $25
Current: $7.39
Upside: +238.29%
Ionis Pharmaceuticals
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $45.14
Upside: +6.34%
Blueprint Medicines
Oct 27, 2023
Maintains: Equal-Weight
Price Target: $59 → $63
Current: $110.36
Upside: -42.91%
Akero Therapeutics
Oct 11, 2023
Maintains: Overweight
Price Target: $70 → $33
Current: $22.38
Upside: +47.45%
ORIC Pharmaceuticals
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $7.52
Upside: +259.04%
Y-mAbs Therapeutics
Aug 14, 2023
Maintains: Underweight
Price Target: $7 → $5
Current: $11.37
Upside: -56.02%
Third Harmonic Bio
Aug 11, 2023
Maintains: Equal-Weight
Price Target: $5 → $7
Current: $12.24
Upside: -42.81%
Karyopharm Therapeutics
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $0.80
Upside: +400.00%
AlloVir
Aug 7, 2023
Reiterates: Overweight
Price Target: $20
Current: $0.74
Upside: +2,621.09%
Iovance Biotherapeutics
May 23, 2023
Maintains: Outperform
Price Target: $20 → $23
Current: $7.73
Upside: +197.54%
Senti Biosciences
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.39
Upside: +412.82%
Rocket Pharmaceuticals
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $19.78
Upside: +127.50%
Xilio Therapeutics
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.89
Upside: +1,023.60%
Allakos
Jan 27, 2023
Maintains: Equal-Weight
Price Target: $6 → $8
Current: $0.84
Upside: +851.70%
Taysha Gene Therapies
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $2.16
Upside: +38.89%
Vir Biotechnology
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $8.85
Upside: +238.98%
IGM Biosciences
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $6.40
Upside: +368.75%
iTeos Therapeutics
Oct 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $14.44
Upside: -
Mersana Therapeutics
May 8, 2018
Initiates: Outperform
Price Target: n/a
Current: $1.86
Upside: -
Ultragenyx Pharmaceutical
Nov 3, 2017
Maintains: Outperform
Price Target: n/a
Current: $40.96
Upside: -
Amicus Therapeutics
Jul 12, 2017
Maintains: Outperform
Price Target: n/a
Current: $9.85
Upside: -